Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and Myositis.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
05 Jul 2024
Historique:
received: 28 05 2024
accepted: 29 05 2024
medline: 5 7 2024
pubmed: 5 7 2024
entrez: 5 7 2024
Statut: aheadofprint

Résumé

Immune checkpoint therapies can drive antitumor responses and benefit patients but can also induce life-threatening immune-related adverse events such as myocarditis and myositis. These immune-related adverse events are rare but carry substantial morbidity and mortality. In this issue, Siddiqui and colleagues use single-cell RNA and T-cell receptor sequencing to identify novel cellular subsets and propose various mechanisms that could contribute to the pathogenesis of immune checkpoint inhibitor-associated myocarditis and myositis. These new insights should help move the field toward the development of improved treatment and prevention options, ultimately improving patient outcomes. See related article by Siddiqui et al., p. XX (1).

Identifiants

pubmed: 38967235
pii: 746276
doi: 10.1158/2326-6066.CIR-24-0506
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

OF1-OF2

Informations de copyright

©2024 American Association for Cancer Research.

Auteurs

Reilly G Fankhauser (RG)

Vanderbilt University Medical Center, Medical Scientist Training Program, Nashville, Tennessee.

Douglas B Johnson (DB)

Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

Javid J Moslehi (JJ)

Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine, San Francisco, California.

Justin M Balko (JM)

Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Classifications MeSH